Compensation to patient [Regulatives / Guidelines]

posted by NK – India, 2025-01-24 05:39 (146 d 11:57 ago) – Posting: # 24346
Views: 1,771

Dear Pharma_88,

❝ For Bioequivalence study conducted on patients, do we need to provide financial compensation to patients for the participation i.e. Housing or blood loss for Pharmacokinetic evaluation? any guideline from DCGI/ICMR or any regulatory body?


Please refer ICH- GCP (E6) R3, 1.2.8 of ANNEX I

If the trial participants are compensated for their participation in the trial, the IRB/IEC should review both the amount and method of payment to participants to assure that neither presents problems of coercion or undue influence on the trial participants. Payments to a participant should be prorated and not wholly contingent on completion of the trial by the participant. Reasonable reimbursement of participants for travel and lodging is not typically coercive.


Regards
NK


Edit: Guideline linked. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,677 registered users;
36 visitors (0 registered, 36 guests [including 10 identified bots]).
Forum time: 18:36 CEST (Europe/Vienna)

Philosophy, like medicine, has plenty of drugs, few good remedies,
and hardly any specific cures.    Sebastien-Roch Nicolas de Chamfort

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5